{"type":"trials","record":{"id":87184,"source_id":"isrctn","external_id":"ISRCTN60816411","title":"Meso-zeaxanthin Ocular Supplementation Trial (MOST)","brief_summary":"Age-related macular degeneration (AMD) is the most common cause of blind registration in the western world. It is estimated that AMD affects approximately 1.4 million individuals in the United States, 417,000 people in the United Kingdom and 70,000 people in the Republic of Ireland, and this number is likely to increase due to increasing longevity. Although the aetiological mechanisms leading to AMD are uncertain, there is a growing consensus that cumulative short wavelength (blue) light damage and/or oxidative stress play a role. The central retina, known as the macula, is responsible for central, colour and fine-detail vision. A pigment, composed of the three dietary hydroxycarotenoids, meso-zeaxanthin (MZ), lutein (L) and zeaxanthin (Z) (MZ is also formed in the retina following conversion from L), accumulates at the macula where it is known as macular pigment (MP). MP is a blue light filter and a powerful antioxidant, and is therefore believed to protect against AMD. In addition, there is good reason to believe why supplementation with MZ, L and Z would enhance a patient's retinal sensitivity. Several studies have investigated the relationship between dietary and serum concent…","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"Macuvision Europe Limited (UK)","enrollment":50,"countries":["Ireland"],"start_date":"2008-10-01","completion_date":"2010-01-01","last_update_date":"2011-12-07","source_url":"https://www.isrctn.com/ISRCTN60816411","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN60816411; retrieved 2026-09-25","interventions":["Macushield™/MacuHealth with LMZ (Meso-zeaxanthin, Lutein and Zeaxanthin)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["MP optical density (including its entire spatial profile), as measured by heterochromatic flicker photometry [HFP]. Pri…","1. Assessment of retinal sensitivity using microperimetry 2. Serum L and Z (including MZ) concentrations as measured by…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration (AMD)","Patients were randomised to: 1. Intervention group: one tablet of Macushield™/MacuHealth with LMZ (dosage: 10 mg L, 10…","results","Participant information sheet","Study website","Macushield™/MacuHealth with LMZ (Meso-zeaxanthin, Lutein and Zeaxanthin)","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn60816411","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2008-10-01 to 2010-01-01","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.595Z","intervention":["Macushield™/MacuHealth with LMZ (Meso-zeaxanthin, Lutein and Zeaxanthin)","Drug"],"participants":50,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["MP optical density (including its entire spatial profile), as measured by heterochromatic flicker photometry [HFP]. Pri…","1. Assessment of retinal sensitivity using microperimetry 2. Serum L and Z (including MZ) concentrations as measured by…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: longevity, age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87184","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}